[go: up one dir, main page]

AR133022A1 - Anticuerpos de nectina-4 y conjugados anticuerpo-fármaco - Google Patents

Anticuerpos de nectina-4 y conjugados anticuerpo-fármaco

Info

Publication number
AR133022A1
AR133022A1 ARP240101583A ARP240101583A AR133022A1 AR 133022 A1 AR133022 A1 AR 133022A1 AR P240101583 A ARP240101583 A AR P240101583A AR P240101583 A ARP240101583 A AR P240101583A AR 133022 A1 AR133022 A1 AR 133022A1
Authority
AR
Argentina
Prior art keywords
seq
ident
comprises seq
lcdr2
hcdr2
Prior art date
Application number
ARP240101583A
Other languages
English (en)
Inventor
Jeffrey Streetman Boyles
Kyla Elizabeth Driscoll
Omar Duramad
Qianxu Guo
Rikke Bæk Holmgaard
Kevin Charles Lindquist
Joshua Inshik Park
Divya Sagar
Mohan Srinivasan
Petra Verdino
Jieyu Zhou
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of AR133022A1 publication Critical patent/AR133022A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68037—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a camptothecin [CPT] or derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente descripción proporciona conjugados fármaco-anticuerpo de nectina-4 y composiciones farmacéuticas de estos, y métodos de uso para el tratamiento del cáncer. Reivindicación 1: Un anticuerpo que se une a la nectina-4 humana, en donde el anticuerpo comprende una región variable de cadena pesada (HCVR) y una región variable de cadena ligera (LCVR), en donde la HCVR comprende regiones determinantes de complementariedad de la cadena pesada (HCDR) HCDR1, HCDR2, y HCDR3, y la LCVR comprende regiones determinantes de complementariedad de la cadena ligera (LCDR) LCDR1, LCDR2, y LCDR3, en donde: a) la HCDR1 comprende la sec. con núm. de ident.: 4, la HCDR2 comprende la sec. con núm. de ident.: 5, la HCDR3 comprende la sec. con núm. de ident.: 6, la LCDR1 comprende la sec. con núm. de ident.: 7, la LCDR2 comprende la sec. con núm. de ident.: 8, y la LCDR3 comprende la sec. con núm. de ident.: 9; b) la HCDR1 comprende la sec. con núm. de ident.: 18, la HCDR2 comprende la sec. con núm. de ident.: 19, la HCDR3 comprende la sec. con núm. de ident.: 20, la LCDR1 comprende la sec. con núm. de ident.: 21, la LCDR2 comprende la sec. con núm. de ident.: 22, y la LCDR3 comprende la sec. con núm. de ident.: 23; c) la HCDR1 comprende la sec. con núm. de ident.: 28, la HCDR2 comprende la sec. con núm. de ident.: 29, la HCDR3 comprende la sec. con núm. de ident.: 30, la LCDR1 comprende la sec. con núm. de ident.: 31, la LCDR2 comprende la sec. con núm. de ident.: 32, y la LCDR3 comprende la sec. con núm. de ident.: 33; d) la HCDR1 comprende la sec. con núm. de ident.: 38, la HCDR2 comprende la sec. con núm. de ident.: 39, la HCDR3 comprende la sec. con núm. de ident.: 40, la LCDR1 comprende la sec. con núm. de ident.: 41, la LCDR2 comprende la sec. con núm. de ident.: 42, y la LCDR3 comprende la sec. con núm. de ident.: 43; e) la HCDR1 comprende la sec. con núm. de ident.: 48, la HCDR2 comprende la sec. con núm. de ident.: 49, la HCDR3 comprende la sec. con núm. de ident.: 50, la LCDR1 comprende la sec. con núm. de ident.: 41, la LCDR2 comprende la sec. con núm. de ident.: 42, y la LCDR3 comprende la sec. con núm. de ident.: 51; f) la HCDR1 comprende la sec. con núm. de ident.: 56, la HCDR2 comprende la sec. con núm. de ident.: 57, la HCDR3 comprende la sec. con núm. de ident.: 58, la LCDR1 comprende la sec. con núm. de ident.: 59, la LCDR2 comprende la sec. con núm. de ident.: 60, y la LCDR3 comprende la sec. con núm. de ident.: 61; g) la HCDR1 comprende la sec. con núm. de ident.: 66, la HCDR2 comprende la sec. con núm. de ident.: 67, la HCDR3 comprende la sec. con núm. de ident.: 68, la LCDR1 comprende la sec. con núm. de ident.: 69, la LCDR2 comprende la sec. con núm. de ident.: 70, y la LCDR3 comprende la sec. con núm. de ident.: 71; o h) la HCDR1 comprende la sec. con núm. de ident.: 76, la HCDR2 comprende la sec. con núm. de ident.: 77, la HCDR3 comprende la sec. con núm. de ident.: 78, la LCDR1 comprende la sec. con núm. de ident.: 69, la LCDR2 comprende la sec. con núm. de ident.: 70, y la LCDR3 comprende la sec. con núm. de ident.: 79.
ARP240101583A 2023-06-20 2024-06-19 Anticuerpos de nectina-4 y conjugados anticuerpo-fármaco AR133022A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202363509077P 2023-06-20 2023-06-20

Publications (1)

Publication Number Publication Date
AR133022A1 true AR133022A1 (es) 2025-08-20

Family

ID=93936206

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP240101583A AR133022A1 (es) 2023-06-20 2024-06-19 Anticuerpos de nectina-4 y conjugados anticuerpo-fármaco

Country Status (4)

Country Link
US (1) US20250000991A1 (es)
JP (2) JP7689606B2 (es)
AR (1) AR133022A1 (es)
WO (1) WO2024263630A1 (es)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006216291B2 (en) * 2005-02-27 2011-01-27 Institute For Antibodies Co., Ltd. Anti-IgSF4 antibody and utilization of the same
WO2015057906A1 (en) * 2013-10-16 2015-04-23 Janssen Biotech, Inc. Cd200 receptor 1 agonists
TWI870338B (zh) * 2017-06-05 2025-01-21 美商艾澤西公司 粘附分子-4結合蛋白及其使用方法
ES3014740T3 (en) * 2020-01-31 2025-04-24 Innate Pharma Treatment of cancer
EP4208259A2 (en) * 2020-09-04 2023-07-12 NovaRock Biotherapeutics, Ltd. Nectin-4 antibodies and uses thereof
CA3212651A1 (en) * 2021-03-31 2022-10-06 Emergence Therapeutics Ag Anti-nectin-4-antibodies and uses thereof
US20240269307A1 (en) * 2021-04-26 2024-08-15 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Anti-nectin-4 antibody and anti-nectin-4 antibody-drug conjugate, and medicinal use thereof
WO2023025243A1 (zh) * 2021-08-27 2023-03-02 石药集团巨石生物制药有限公司 抗Nectin-4抗体、药物缀合物及其制备方法和用途

Also Published As

Publication number Publication date
TW202515913A (zh) 2025-04-16
JP2025011033A (ja) 2025-01-23
JP2025081387A (ja) 2025-05-27
JP7689606B2 (ja) 2025-06-06
US20250000991A1 (en) 2025-01-02
WO2024263630A1 (en) 2024-12-26

Similar Documents

Publication Publication Date Title
PE20210045A1 (es) Anticuerpos agonistas contra pd-1 y usos de estos
PE20210132A1 (es) Anticuerpos anti-cd3 y usos de estos
PE20212088A1 (es) Anticuerpos anti-tau y uso de los mismos
PE20220218A1 (es) Conjugados de anticuerpo-farmaco inhibidores de mcl-1 y sus metodos de uso
AR126019A1 (es) Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
PE20240363A1 (es) Anticuerpos anti-ccr8 y usos de los mismos
PE20221337A1 (es) Anticuerpos trem2 y usos de estos
PE20231049A1 (es) Conjugados de anticuerpo y farmaco basados en eribulina y metodos para su uso
PE20230389A1 (es) Proteinas que comprenden dominios de union al antigeno de cd3 y usos de estas
PE20200011A1 (es) ANTICUERPOS ANTI-PEPTIDO BETA AMILOIDE N3pGlu Y SUS USOS
PE20200294A1 (es) Anticuerpos que se unen especificamente a pd-1 y metodos de uso
MX2019007848A (es) Anticuerpos anti-pd-1 y usos de los mismos.
CO6230999A2 (es) Anticuerpo anti-esclerostina
AR110719A1 (es) Anticuerpos humanos a la toxina hemolisina a de s. aureus
PE20181326A1 (es) Anticuerpos que se unen especificamente a pd-1 y sus usos
AR103713A1 (es) Anticuerpos contra tau y sus usos
NZ583605A (en) Humanized anti-cxcr5 antibodies, derivatives thereof and their uses
CU24636B1 (es) Anticuerpos que reconocen tau en los residuos 257-271 o 320-334 de la seq id no: 1
NZ610294A (en) Human antibodies to human tnf-like ligand 1a (tl1a)
AR123480A1 (es) Moléculas de unión terapéuticas
RU2018120695A (ru) Связывающие молекулы, специфичные в отношении asct2, и их применения
AR123083A1 (es) Proteínas que comprenden dominios de unión al antígeno hla-g y sus usos
NZ592436A (en) Treatment with anti-alpha2 integrin antibodies
AR104906A1 (es) Anticuerpos dirigidos a la proteína morfogenética ósea 9 (bmp9) y métodos a partir de estos
RU2017137496A (ru) Средство для лечения множественной миеломы (ММ)